4ny9
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | ''' | + | ==Crystal Structure Of the Human PXR-LBD In Complex With N-{(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl}-3-hydroxy-3-methylbutanamide== |
+ | <StructureSection load='4ny9' size='340' side='right' caption='[[4ny9]], [[Resolution|resolution]] 2.80Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[4ny9]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NY9 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4NY9 FirstGlance]. <br> | ||
+ | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2Q4:N-{(2R)-1-[(4S)-4-(4-CHLOROPHENYL)-4-HYDROXY-3,3-DIMETHYLPIPERIDIN-1-YL]-3-METHYL-1-OXOBUTAN-2-YL}-3-HYDROXY-3-METHYLBUTANAMIDE'>2Q4</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene><br> | ||
+ | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ny9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ny9 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ny9 RCSB], [http://www.ebi.ac.uk/pdbsum/4ny9 PDBsum]</span></td></tr> | ||
+ | <table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | High affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis. | ||
- | The | + | The Discovery of CCR1 Antagonist, BMS-817399, for the Treatment of Rheumatoid Arthritis.,Santella J, Duncia JV, Gardner D, Wu H, Dhar MT, Cavallaro CL, Tebben AJ, Carter PH, Barrish JC, Yarde M, Briceno S, Cvijic ME, Grafstrom R, Liu R, Patel S, Watson A, Yang G, Rose A, Vickery R, Caceres Cortes J, Caporuscio C, Camac D, Khan J, An Y, Foster W, Davies P, Hynes J J Med Chem. 2014 Aug 7. PMID:25101488<ref>PMID:25101488</ref> |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | == References == | |
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Camac, D M.]] | ||
+ | [[Category: Khan, J A.]] | ||
+ | [[Category: Activation function]] | ||
+ | [[Category: Af]] | ||
+ | [[Category: Ccr1]] | ||
+ | [[Category: Chemokine receptor-1]] | ||
+ | [[Category: Ligand binding domain]] | ||
+ | [[Category: Mdr1]] | ||
+ | [[Category: Multi-drug resistance gene-1]] | ||
+ | [[Category: Nr]] | ||
+ | [[Category: Nuclear receptor]] | ||
+ | [[Category: Pregnane x receptor]] | ||
+ | [[Category: Pxr]] | ||
+ | [[Category: Steroid receptor coactivator-1]] | ||
+ | [[Category: Transcription-transcription inhibitor complex]] |
Revision as of 08:44, 27 August 2014
Crystal Structure Of the Human PXR-LBD In Complex With N-{(2R)-1-[(4S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl]-3-methyl-1-oxobutan-2-yl}-3-hydroxy-3-methylbutanamide
|